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ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe
respiratory illness and has a high mortality of 34%. However, since its discovery in
2012, an effective vaccine has not been developed for it. To develop a vaccine
against multiple strains of MERS-CoV, we targeted spike glycoprotein (S) using
prime-boost vaccination with DNA and insect cell-expressed recombinant proteins
for the receptor-binding domain (RBD), S1, S2, SΔTM, or SΔER. Our S subunits were
generated using an S sequence derived from the MERS-CoV EMC/2012 strain. We ex-
amined humoral and cellular immune responses of various combinations with DNA
plasmids and recombinant proteins in mice. Mouse sera immunized with SΔER DNA
priming/SΔTM protein boosting showed cross-neutralization against 15 variants of
S-pseudovirions and the wild-type KOR/KNIH/002 strain. In addition, these immuniza-
tions provided full protection against the KOR/KNIH/002 strain challenge in human
DPP4 knock-in mice. These findings suggest that vaccination with the S subunits de-
rived from one viral strain can provide cross-protection against variant MERS-CoV
strains with mutations in S. DNA priming/protein boosting increased gamma inter-
feron production, while protein-alone immunization did not. The RBD subunit alone
was insufficient to induce neutralizing antibodies, suggesting the importance of
structural conformation. In conclusion, heterologous DNA priming with protein
boosting is an effective way to induce both neutralizing antibodies and cell-
mediated immune responses for MERS-CoV vaccine development. This study sug-
gests a strategy for selecting a suitable platform for developing vaccines against
MERS-CoV or other emerging coronaviruses.
IMPORTANCE Coronavirus is an RNA virus with a higher mutation rate than DNA vi-
ruses. Therefore, a mutation in S-protein, which mediates viral infection by binding
to a human cellular receptor, is expected to cause difficulties in vaccine develop-
ment. Given that DNA-protein vaccines promote stronger cell-mediated immune re-
sponses than protein-only vaccination, we immunized mice with various combina-
tions of DNA priming and protein boosting using the S-subunit sequences of the
MERS-CoV EMC/2012 strain. We demonstrated a cross-protective effect against wild-
type KOR/KNIH/002, a strain with two mutations in the S amino acids, including one
in its RBD. The vaccine also provided cross-neutralization against 15 different
S-pseudotyped viruses. These suggested that a vaccine targeting one variant of S
can provide cross-protection against multiple viral strains with mutations in S. The
regimen of DNA priming/Protein boosting can be applied to the development of
other coronavirus vaccines.
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Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in theKingdom of Saudi Arabia in 2012 and has been causing recurrent infectious
outbreaks of respiratory illness in humans (1). At the end of January 2020, 2,519
laboratory-confirmed cases of MERS worldwide, including 866 associated deaths and a
mortality rate of 34.3%, were reported. MERS is a zoonotic disease with bats and
dromedary camels, playing an important role in its emergence (2). MERS-CoV is
transmitted to humans through close contact with dromedaries (3). Vaccination is
expected to be an efficacious strategy in preventing individuals and animals against
contracting MERS-CoV infections, but no vaccine or specific treatment for MERS has
been globally approved yet. To date, several MERS-CoV vaccine candidates have been
developed, including DNA, subunit protein, nanoparticle, inactivated whole-virus, and
recombinant viral vector-based such as adenoviral vectors, modified vaccinia virus
Ankara, and recombinant measles virus (4–6).
MERS-CoV is an enveloped virus with a positive-sense single-stranded RNA genome
(7). Among the four structural proteins of MERS-CoV spike (S), envelope, membrane,
and nucleocapsid, the S glycoprotein is expected as the candidate molecule for an
appropriate vaccine to induce neutralizing antibodies (8). S is a class 1 viral fusion
protein that mediates host receptor attachment and fusion of the viral and cellular
membranes. S is trimeric, and each protomer is synthesized as a single polypeptide
chain of 1,395 amino acids. The S glycoprotein is cleaved into the receptor-binding
subunit S1 and the membrane fusion subunit S2 by host proteases during the infection
process (9–11). S1 and S2 remain noncovalently bound in the prefusion conformation
(12). The S1 subunit comprises the apex of the S trimer, including the receptor-binding
domains (RBDs), and stabilizes the prefusion state of the S2 fusion machinery, which is
anchored in the viral membrane. S is further cleaved by host proteases at the so-called
“S2” site located immediately upstream of the fusion peptide. This cleavage has been
proposed to activate the protein for membrane fusion via large-scale, irreversible
conformational changes.
Most recombinant vaccine candidates use full-length S or its truncated version of S1.
Because the conformation of RBD in full-length S and truncated versions may differ, the
recombinant RBD subunit protein itself may not induce neutralizing antibodies as
efficiently as a larger subunit such as S1 or transmembrane deleted S (SΔTM) (13).
Hence, the goal of our study was to systematically investigate the effect of S subunits,
including RBD, S1, S2, and SΔTM, and the heterologous prime-boost regimen on
protective immune responses in mice.
In this study, we produced DNA plasmids encoding several S subunits and recom-
binant proteins in insect cells for RBD, S1, S2, and SΔTM and compared the protective
immune responses of various combinations in mice. The results of this study are
expected to contribute to the development of an appropriate MERS-CoV vaccine
strategy using DNA prime-protein boost with the S subunit.
RESULTS
Selection of MERS-CoV SER as a DNA vaccine vector. (i) Construction of
MERS-CoV S subunit DNA plasmids. To examine the immunogenicity of MERS-CoV S
subunits as a DNA vaccine, human codon-optimized pSΔER, pSΔTM, pS1, pRBD, and
pS2 DNA were generated using a mammalian expression vector. pSΔER (amino acids
[aa] 1 to 1338) has a truncated S gene, including the deletion of the endoplasmic
reticulum (ER) retention signal (aa 1339 to 1353), pSΔTM (aa 1 to 1296) with a deletion
from the transmembrane domain, pS1 (aa 1 to 751), pRBD (aa 1 to 18 and 358 to 606),
and pS2 (aa 1 to 18 and 752 to 1296). Both pRBD and pS2 have an additional signal
peptide (aa 1 to 18) sequence at the N terminus to facilitate the extracellular secretion
of recombinant proteins.
S-protein expression from pSΔER, pSΔTM, pS1, pRBD, or pS2 DNA was verified by
Western blot analysis. HEK293T cells were transfected with each DNA plasmid or mock
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vector as the negative control. The bands corresponding to the MERS-CoV SΔER protein
(148 kDa), SΔTM protein (143 kDa), S1 protein (94 kDa), RBD protein (27 kDa),
and S2 protein (66 kDa) in cell lysates and cell culture supernatants were detected
(Fig. 1A). In cell lysates, pSΔER transfection exhibited a higher expression level of
corresponding protein than pSΔTM, pS1, and pRBD transfection. The bands of the SΔER
protein with a size larger than expected were assumed glycosylated proteins and those
with a smaller size as cleaved proteins. In contrast to the protein expression level in cell
lysates, pS1 and pRBD transfection showed even higher expression levels of secreted
proteins in cell culture supernatant than pSΔER and pSΔTM. Interestingly, pSΔER
showed the band with a size similar to that of pSΔTM and other smaller bands in cell
culture supernatant, indicating the secretion of proteins. pS2 showed the bands with a
size larger and smaller than expected as well as in the supernatant. These results
indicated that recombinant SΔTM, S1, RBD, and S2 proteins were expressed by the
transfected cells and secreted.
(ii) Antibody responses induced by MERS-CoV S subunit DNA plasmids. To
investigate the level of in vivo humoral immune responses induced by various MERS-
CoV S subunit DNA vaccines, 50 g of each DNA vector was administered via the
intramuscular (i.m.) route three times at 2-week intervals. Sera were collected 2 weeks
after the last immunization and assessed for the presence of MERS-CoV RBD-specific
antibody by ELISA. As expected, RBD protein (358 to 606 aa)-specific antibody re-
sponses were not detected in the mice immunized with pS2 (1 to 18 and 752 to 1,296
aa) but were present in those immunized with pSΔER, pSΔTM, pS1, and pRBD DNA (Fig.
1B). The pSΔER DNA-immunized group presented a higher anti-RBD IgG titer than
pSΔTM and pRBD DNA-immunized group. There was no statistically significant differ-
ence between the pSΔER and pS1 group, but the mean value of the pSΔER group was
higher than that of the pS1 group.
Neutralizing activity was determined using the EMC/2012 and KOR/KNIH/002 strains
of MERS-CoV pseudovirion containing the luciferase reporter gene. Diluted sera were
incubated with each pseudovirion, and inhibition of pseudovirus entry into target cells
was assessed by measuring luciferase activity in cell lysates. The results were expressed
as relative luciferase units (RLU). Lower RLU value indicated a higher level of inhibition
of pseudovirion infection into the cells. pSΔER and pS1 DNA immunization induced a
statistically significant increase in neutralizing antibody in the sera (P  0.05 at all of the
serum dilutions), but the pSΔTM, pRBD, and pS2 DNA-immunized mice did not show
statistically significant differences compared to phosphate-buffered saline (PBS)-
administered mice (Fig. 1C). In both EMC/2012 and KOR/KNIH/002 strains, pSΔER
DNA-immunized mice showed the highest neutralizing activity compared to the other
DNA-immunized groups. These results indicate that the SΔER DNA plasmid is the most
effective construct to induce antibody immune responses in mice. Therefore, pSΔER
was selected as the final DNA vaccine vector to be used for DNA priming.
pSER DNA prime-STM protein boost induced comparable humoral immune
responses to S1 and STM protein subunits. To examine the effect of boosting with
various S subunit proteins after DNA priming, recombinant SΔTM (1 to 1,296 aa), S1 (1
to 751 aa), S2 (752 to 1,296 aa), and RBD (358 to 606 aa) proteins were produced in SF9
insect cells by using the baculovirus system with a protein purity of 85%, as described
previously (14). Mice were immunized i.m. with DNA only, DNA prime followed by a
protein boost, or protein only. The following combinations of MERS-CoV S DNA and/or
proteins were used: (i) three times with pSΔER DNA; (ii) pSΔER DNA two times, followed
by various S-subunit proteins (SΔTM, S1, S2, and RBD); (iii) SΔTM protein, S1 protein,
and RBD protein; or (iv) PBS as a negative control. All the proteins were adjuvanted with
alum hydroxide. Serum samples were collected 2 weeks after the last immunization,
and SΔTM-, S1-, and RBD-specific antibody titers in mice sera were determined by
ELISA. As shown in Fig. 2A, the mice immunized with pSΔER DNA prime (two doses)–
SΔTM protein boost (one dose) showed the highest antibody titers against each of the
SΔTM, S1, and RBD antigens within the DNA prime-protein boost-vaccinated group.
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FIG 1 Comparison of immunogenicity induced by various MERS-CoV S subunit DNA constructs. (A) S subunit protein expression in 293T cells, including
secretion into cell culture supernatants, was confirmed by Western blotting after transfection with each DNA construct. (Mock, Mock plasmid; pSΔER, SΔER
plasmid; pSΔTM, SΔTM plasmid; pS1, S1 plasmid; pRBD, RBD (signal peptide) plasmid; pS2, S2 (ΔTM  signal peptide) plasmid. (B and C) Immunogenicity of
various MERS-CoV S subunit DNA constructs. BALB/c mice (n  5) were i.m. immunized with 50 g of pSΔER, pSΔTM, pS1, pRBD, and pS2 DNA or 50 l of PBS
three times (at days 0, 14, and 28). Sera were collected 14 days after the third immunization (at day 42), and RBD protein-specific serum IgG level was measured
by ELISA. Significant differences are indicated as follows: *, P  0.05; **, P  0.01; ***, P  0.001; and NS, not significant. (B). Neutralizing activity of 1/4-, 1/16-,
(Continued on next page)
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SΔTM- and S1-specific antibody titers of pSΔER DNA prime-SΔTM protein boost-
vaccinated group were significantly higher than those of the pSΔER DNA-vaccinated
group but were not statistically significant compared to those of the SΔTM protein-
vaccinated group. The RBD-specific antibody titer of the pSΔER DNA prime-SΔTM
protein boost-vaccinated group was higher than that of the pSΔER DNA-vaccinated
group and lower than that of the SΔTM protein-vaccinated group.
In addition, neutralizing activity was determined using S-pseudovirions obtained
from MERS-CoV EMC/2012 and KOR/KNIH/002 strains. Similar to the results of the
antibody titer, the mice immunized with pSΔER DNA prime-SΔTM protein boost
vaccination showed the highest neutralizing activity among the DNA prime-protein
boost groups (Fig. 2B). The neutralizing activity of pSΔER DNA prime–SΔTM protein
boost-vaccinated group was higher than that of the pSΔER DNA-vaccinated group at a
1/50 serum dilution and comparable to that of the SΔTM protein-vaccinated group
(1/10 dilution, no significance; 1:50 dilution, P  0.01). However, the RBD protein-
vaccinated group showed minimal neutralizing activity against the S-pseudovirions of
both EMC/2012 and KOR/KNIH/002 strains, while RBD-binding IgG titer was not statis-
tically different from that of SΔTM- and S1-protein vaccination. These data demon-
strated that immunization with the pSΔER DNA prime-SΔTM protein is an effective
vaccination regimen to induce potent humoral immune responses in mice. Similarly,
vaccination with SΔTM or S1 protein also induced robust humoral responses.
pSER DNA prime-STM protein boost elevated cell-mediated immune re-
sponse. Cell-mediated immune responses were evaluated by determining the levels of
cytokines secreted by cells. Gamma interferon (IFN-) is the typical Th1-type cytokine
and is produced by CD4 and CD8 T cells. The IFN- level was measured by a mouse
IFN- enzyme-linked immunosorbent spot (ELISpot) assay. MERS-CoV S pooled peptide
was used for eliciting S-protein-specific CD8 T-cell response. Unrelated gag peptide
was used as the negative control, and PMA/ionomycin was used as a positive control.
T-cell responses were measured 14 days after the last vaccination. The mice vaccinated
with DNA prime-protein boost vaccine showed S pooled peptide-specific CD8 T-cell-
mediated immune response as determined by IFN--secreting splenocyte counts (Fig.
2C). However, the protein subunit-vaccinated group showed no IFN--secreting cells.
These data indicated that the pSΔER DNA prime-SΔTM protein boost vaccine generated
a higher T-cell-mediated immune response.
SER DNA prime-STM protein boost induced neutralizing antibodies against
wild-type MERS-CoV strain. To determine the protective immune response against
natural infection, the neutralizing antibody titer against wild-type MERS-CoV KOR/KNIH/
002 strain was determined based on the 50% plaque reduction/neutralization titer
(PRNT50). The results showed a pattern similar to the neutralizing activity against
pseudovirions described earlier. The mice immunized with the pSΔER DNA prime–
SΔTM protein boost showed the highest wild-type virus-neutralizing activity among the
DNA prime–protein boost-vaccinated groups (Fig. 3). The wild-type virus-neutralizing
activity in the pSΔER DNA prime-SΔTM protein boost group was higher than that in the
pSΔER DNA-treated group and comparable to the SΔTM protein-treated or S1 protein-
treated group. However, the RBD protein-vaccinated group did not show neutralizing
activity against the wild-type MERS-CoV strain. Therefore, these results indicated that
our pSΔER DNA prime-SΔTM protein boost vaccine induced neutralizing antibodies
against the wild-type MERS-CoV strain comparable to adjuvanted recombinant SΔTM
and S1 protein.
pSER DNA prime-STM protein boost induced cross-protective neutralizing
activity against various MERS-CoV S-pseudovirions. To evaluate the cross-protective
neutralizing activity of DNA prime-protein boost vaccination, we performed a pseudo-
FIG 1 Legend (Continued)
and 1/64-diluted sera against MERS-CoV EMC/2012 and KOR/KNIH/002 S-pseudovirions was analyzed by measuring luciferase activity (C). The results are
expressed as means  the standard deviations (SD). Significant differences are indicated as follows: *, P  0.05; **, P  0.01; ***, P  0.001; and ****, P  0.0001.
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FIG 2 Humoral and cellular immune responses induced by immunization with pSΔER DNA/various recombinant MERS-CoV S subunit proteins. Enhanced
immunogenicity by priming with pSΔER DNA and boosting with various recombinant MERS-CoV S subunit proteins. (A) Antibody responses induced by DNA
prime-protein boost. BALB/c mice (n  5) were i.m. immunized with pSΔER DNA (50 g) two times, followed by various S-proteins (SΔTM, S1, S2, and RBD, 1 g
each), and pSΔER DNA (50 g), SΔTM protein (1 g), S1 protein (1 g), RBD protein (1 g), or PBS three times as controls. All of the proteins were adjuvanted
with alum hydroxide. Mouse sera were collected 14 days after the last immunization (at day 42), and their titers were analyzed by ELISA. Serum IgG titers were
measured against SΔTM, S1, and RBD proteins. IgG titer is expressed as the reciprocal log2 of serum dilution showing an absorbance of 0.2 at 450 nm. The results
are expressed as means  the SD. Significant differences are indicated as follows: *, P  0.05; **, P  0.01; ***, P  0.001; and NS, not significant. Statistical
significance was compared between the pSΔER DNA-immunized group, or SΔTM protein-immunized group against the pSΔER DNA prime-SΔTM protein boost
immunized group. (B) Neutralizing activity of DNA prime-protein boost vaccine against with MERS-CoV vaccine. The neutralizing effect of serially diluted sera
(1/10, 1/50, 1/250, 1/1,250, and 1/6,250) against EMC/2012 S-pseudovirions and KOR/KNIH/002 S-pseudovirions was assessed by measuring luciferase activity.
The results are indicated as means  the SD. Significant differences are indicated as follows: *, P  0.05; **, P  0.01; ***, P  0.001; NS, not significant. (C)
(Continued on next page)
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virus neutralization assay against 15 different MERS-CoV S-pseudovirions. Fifteen MERS-
CoV S gene sequences were selected from GenBank. Three pseudovirions were con-
structed using each DNA plasmid encoding SΔER of EMC/2012, KOR/KNIH/002, and
England1, and 12 of them were constructed based on the EMC/2012 strain S sequence
with mutations only in the RBD region as described previously (2). Sera from pSΔER
DNA prime-SΔTM protein boost-, pSΔER DNA-, and SΔTM protein-immunized group
were tested against each pseudovirion. The neutralizing activity of pSΔER DNA prime-
SΔTM protein boost was comparable to that of SΔTM protein vaccination and higher
than that of pSΔER DNA immunization against all the 15 pseudovirions. We demon-
strated that pSΔER DNA prime-SΔTM protein boost vaccine could protect against
infection caused by various MERS-CoV S-pseudovirions (Fig. 4). Thus, our pSΔER DNA
prime-SΔTM protein boost vaccination is expected to be cross-protective against
MERS-CoVs with mutations in the S, which mediates viral entry to the cells.
SER DNA prime-STM protein boost vaccine exhibited a protective effect
against wild-type MERS-CoV infection in mice. MERS-CoV S-protein and human
dipeptidyl peptidase 4 (DPP4) receptor-binding triggers the fusion of the virus and host
cell membrane, and therefore the human DPP4 receptor is essential for MERS-CoV
infection. However, the mouse DPP4 receptor does not play the same role as the
human DPP4 receptor. To investigate the in vivo protective effect of our vaccine
regimen against the wild-type MERS-CoV challenge, human DPP4 receptor knock-in
mice were used. The mice were immunized with the pSΔER DNA prime-SΔTM protein
boost vaccine, pSΔER DNA, or SΔTM protein three times biweekly. Two weeks after the
FIG 2 Legend (Continued)
T-cell immune response induced by DNA prime–protein boost with MERS-CoV vaccine. Vaccinated C57BL/6 mice were sacrificed 14 days after the last
immunization (at day 42), and splenocytes were stimulated with S1, RBD, and S2 pooled peptides. IFN--producing T cells were enumerated by using an ELISpot
assay. There were statistically significant differences between the PBS group versus all three DNA prime-protein boost groups and the SΔTM protein group
(two-tail Mann-Whitney U test). The results are expressed as means  the SD.
FIG 3 In vitro neutralizing effect of MERS-CoV vaccine against the wild-type MERS-CoV strain. Serially
diluted mouse sera were incubated with the wild-type MERS-CoV KOR/KNIH/002 strain, and the mixture
was added to VeroE6 cells. After 3 days, the plaque numbers were counted, and the last dilution factor
showing a value greater than 50% is expressed as the PRNT50 titer. Statistical analyses of each group were
performed with a two-tailed unpaired test. The results are expressed as means  the SD. Significant
differences are indicated as follows: *, P  0.05; **, P  0.01; and ***, P  0.001. There was no statistical
significance between the experimental groups except for the statistically marked experimental group.
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last immunization, the vaccinated mice were challenged intranasally with 2  104 PFU
of the wild-type MERS-CoV KOR/KNIH/002 strain in the Animal Biological Safety Level 3
facility. Survival and body weight changes of each mouse were monitored daily for
14 days. As shown in Fig. 5A, none of the mice in the mock vector-immunized group
survived against the wild-type MERS-CoV infection. On the other hand, all mice in the
pSΔER DNA prime-SΔTM protein boost group and SΔTM protein-vaccinated group
survived. A total of 80% (4/5) mice survived in the pSΔER DNA-vaccinated group
FIG 4 Evaluation of cross-neutralizing activities against various MERS-CoV S-pseudovirions. The neutralizing activities of the DNA prime-protein boost vaccine,
protein vaccine, and DNA vaccine were assessed. Diluted mouse sera (1/10, 1/50, 1/250, 1/1,250, and 1/6,250) were tested for their neutralizing activities against
15 pseudovirions by measuring the luciferase activities of target cells.
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(Fig. 5A). Significant body weight loss was observed in the mock vector-immunized
mice. However, the mice that survived in the other vaccinated groups lost less than
10% of their initial body weight (Fig. 5B). These results demonstrated that pSΔER DNA
prime-SΔTM protein boost vaccination provided protective immunity against wild-type
MERS-CoV infection in vivo.
DISCUSSION
In this study, we found that priming with DNA corresponding to SER and boosting
with the recombinant SΔTM protein of the MERS-CoV EMC/2012 strain induces effective
cross-neutralizing responses against 15 S-pseudovirions and cross-protection against
the wild-type MERS-CoV KOR/KNIH/002 strain both in vitro and in vivo.
Coronavirus is known to have relatively higher genetic stability compared to other
RNA viruses because of the proofreading function of nsp14 (15, 16). However, according
to the analysis of the 2015 South Korean outbreak, the S gene, a target of vaccine
development, was estimated to show a higher evolutionary rate with 6.72  10	3
substitutions/site/year (17) than that for complete MERV-CoV genomes with
1.12  10	3 substitutions per site per year or 9.29  10	4 substitutions/site/year (17,
18). Especially, aa 1020 of S, which is located in a domain required for cell entry, is
FIG 5 In vivo protective effect of MERS-CoV vaccine against wild-type MERS-CoV challenge. Immunization
was performed using a total of 16 hDPP4 knock-in mice (7 to 9 weeks old). hDPP4 knock-in mice were
i.m. immunized with pSΔER DNA two times, followed by SΔTM protein (n  4), pSΔER DNA (n  5), SΔTM
protein (n  4), or PBS (n  3) as the negative control. All proteins were adjuvanted with alum hydroxide.
Two weeks after the third immunization (at day 42), the mice were intranasally challenged with 2  105
PFU of the wild-type MERS-CoV KOR/KNIH/002 strain. The survival rates (A) and body weight changes (B)
for all mice were then monitored daily for 14 days.
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known to be under strong positive selection (18). In addition, a few strains have been
reported as possessing one or two mutations in the RBD of S (17, 18). Therefore, we
speculated whether vaccine candidates derived from an S sequence of a single strain
could provide cross-protection against different MERS-CoV S variants. To represent
mutations in S, we constructed 12 RBD variants based on EMC/2012 S and 3 SΔER
(EMC/2012, England1, and KOR/KNIH/002) pseudovirions and used them to examine
the cross-neutralizing capability of vaccine candidates (14). In contrast to what we
previously found, i.e., that several monoclonal antibodies cannot neutralize an
S-pseudovirion containing even a single different amino acid in RBD (14), the polyclonal
serum produced by our vaccine candidates (pSΔER DNA prime-SΔTM protein boost,
pSΔER DNA, or SΔTM protein) exhibited cross-neutralization against all the 15 pseu-
dovirions. The cross-protection activity of these vaccines against the wild-type KOR/
KNIH/002 strain was also confirmed in PRNT and hDPP4 knock-in mice.
Antibody-dependent enhancement (ADE) of viral entry has been observed in a
variety of viruses, such as dengue virus, HIV-1, Ebola virus, SARS-CoV-1, and MERS-CoV
(6, 19, 20). The role of T cells remains less clear for exacerbated pathogenicity by ADE.
However, some reports have suggested a protective role of CD8 T cells in controlling
Zika virus replication in mice and nonhuman primates (21, 22) and dengue virus
replication in mice (23, 24). When we take T-cell-mediated immune responses by IFN-
production into account, DNA priming-protein boosting vaccination is superior to
protein immunization alone (25–27). While S1 and SΔTM protein immunization induced
neutralizing antibodies against both pseudovirions and the wild-type MERS-CoV strain,
they did not induce IFN- production in response to antigen peptide stimulation. Our
results suggest that DNA priming-protein boosting is a promising strategy to induce
both humoral and cellular immune responses than DNA or protein immunization alone.
Previously, Al-Amri SS et al. reported immunogenicity of candidate MERS-CoV S vac-
cines; only mice immunized with pS and pS1 but not pSΔTM (1 to 1,295 aa) induced
significant levels of S1-specific IgG compared to mock vector immunized group (8).
Similarly, our pSΔTM (1 to 1,296 aa) induced a statistically significant lower level of
RBD-specific IgG than pSΔER. It is not fully explained why pSΔER is superior to pSΔTM
in inducing RBD-specific IgG in our study, but it might be due to a higher level of
protein expression of SΔER and different level of major histocompatibility complex
(MHC) class II presentation of their degraded proteins depending on protein processing
characteristics in the ER or Golgi compartment (28).
Also, Wang L et al. reported full-length S DNA and S1 subunit protein expressed in
mammalian cells as an approach for MERS-CoV vaccine development (13). However, our
study used insect cell-expressed SΔTM subunit protein as the boosting antigen after
DNA priming for MERS-CoV vaccine development. We did not compare the protective
effect of S subunit proteins produced in mammalian cells and insect cells. However,
insect cell-produced recombinant S1 and SΔTM efficiently boosted neutralizing im-
mune responses in mice, although these proteins are known to exhibit different
glycosylation patterns compared to the mammalian cell-expressed proteins. Interest-
ingly, only RBD immunization induced a high level of binding antibodies but did not
induce efficient neutralizing antibodies, suggesting that structural conformation is
important for inducing neutralizing antibodies. Our results indicate that RBD confor-
mation is critical for inducing neutralizing antibodies rather than glycosylated moieties
in S, which is consistent with the observation that mammalian cell-expressed RBD is
often fused to the human IgG Fc region or the foldon trimerization motif to function as
a MERS-CoV vaccine candidate (29–31). Since SΔTM includes the S2 region that is
involved in the fusion of the MERS-CoV virus to the host cell membrane, SΔTM may
enhance the breadth of neutralizing antibodies than S1 (32). Therefore, we chose SΔTM
for producing a booster vaccine and further investigated it: SER DNA priming-protein
boosting with SΔTM provided a higher PRNT50 value against the wild-type MERS-CoV
KOR/KNIH/002 strain than DNA immunization alone, which provided full protection
against the wild-type KOR/KNIH/002 strain challenge in hDPP4 knock-in mice similar to
SΔTM protein immunization alone. In summary, priming with pSΔER DNA and boosting
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with SΔTM protein is an effective way for MERS-CoV vaccine development by increasing
both neutralizing antibody levels and cell-mediated immune responses. This study
provides an important insight for selecting a suitable vaccine platform in developing
vaccines against MERS-CoV or other emerging coronaviruses such as SARS-CoV-2.
MATERIALS AND METHODS
Animals. Six-week-old female BALB/c (Koatech, Pyung Taek, South Korea) and C57BL/6 (Orient Bio,
Sungnam, South Korea) mice were purchased and housed in the Animal Research Facility, International
Vaccine Institute (IVI) under standard laboratory conditions. Human dipeptidyl protease 4 (hDPP4)
knock-in mice were kindly provided by Paul McCray, University of Iowa, and bred at the IVI. Animal
protocols were approved by the Institutional Animal Care and Use Committees of the IVI (2016-004 and
2017-004).
Construction of MERS-CoV subunit S expression plasmids. Human codon-optimized MERS-CoV S
gene of the EMC/2012 isolate (GenBank accession number JX869059) (33) was used for preparing the PCR
template for SΔER (deletion of the ER retention signal: 1 to 1,338 aa), SΔTM (1 to 1,296 aa), S1 (1 to 751
aa), S2 (752 to 1,296 aa), and RBD (358 to 606 aa) cloning with primer sets that contained a restriction
enzyme site (SalI or BamHI). Details of the cloning primers are provided in Table 1. RBD and S2 included
the S leader sequence of the EMC-2012 strain at the N terminus. Each PCR product was cloned into the
mammalian expression vector pCMV/R 8B (34) using SalI or BamHI sites. The gene encoding S of the
KOR/KNIH/002 strain (GenBank accession number KT029139) was synthesized (GenScript, Piscataway, NJ).
Other mutated genes encoding substituted residues in the RBD of S were generated by site-directed
mutagenesis (QuikChange II XL site-directed mutagenesis kit; Agilent Technologies, Santa Clara, CA)
using the EMC/2012 strain S gene as a template. The sequences of strains with mutations in MERS-CoV
RBD residues were obtained from the GenBank database (14). All of the insert genes in the recombinant
pCMV/R 8B plasmids were verified by sequencing (Cosmo Genetech, Seoul, South Korea).
Transfection and Western blot analysis. HEK 293T cells (ATCC, CRL-3216) were transfected by using
Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific, Waltham, MA) according to the
manufacturer’s recommendations, harvested 2 days after transfection, and maintained at 	80°C. Cell
lysates and culture supernatants were resolved by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and transferred to a polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA). The membrane
was incubated with a 1:1,000-diluted sample of rabbit polyclonal IgG (Sino Biological, BDA, Beijing, China,
catalog no. 40069-RP02) to detect SΔER, SΔTM, S1, S2, and RBD overnight at 4°C in blocking buffer (PBS
[Thermo Fisher Scientific], 5% skim milk [BD Bioscience, San Jose, CA], 0.05% Tween 20 [Sigma, St. Louis,
MO]), followed by washing. The blot was further incubated in a blocking buffer with 1:5,000 dilutions of
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Southern Biotech, Birmingham, AL) for 1
h at 22°C and then washed. Detection was performed with the enhanced chemiluminescence reagent
(ELPIS-Biotech, Daejeon, South Korea).
Mouse immunizations. Six-week-old female BALB/c and C57BL/6 mice received MERS-CoV S plas-
mids (50 g) three times at 2-week intervals or two times, followed by boosting with recombinant S
subunit proteins (1 g) adjuvanted with alum hydroxide (Thermo Fisher Scientific) i.m. Mouse sera were
obtained after 14 days of each immunization under anesthesia (intraperitoneal route: ketamine hydro-
chloride [Yuhan Co., Ltd., Seoul, South Korea] and xylazine hydrochloride [Bayer Korea, Seoul, South
Korea]).
Enzyme-linked immunosorbent assay. Recombinant MERS-CoV S subunit protein-specific antibody
levels in the serum were measured by an enzyme-linked immunosorbent assay (ELISA). Ninety-six-well
plates (Thermo Fisher Scientific) were coated with 100 ng/well of SΔTM, S1, or RBD recombinant protein
in 100 l of coating buffer (50 mM sodium bicarbonate [Sigma] in PBS [pH 9.6]) and incubated at 4°C
overnight. After blocking with blocking buffer (1% bovine serum albumin [Merck, Darmstadt, Germany]
in PBS) for 1 h at room temperature, serially diluted serum samples prepared in blocking buffer were
added to the plates; they were then incubated for 1 h at 37°C. Next, HRP-conjugated goat anti-mouse
IgG (1:3,000; Southern Biotech) was added, and the plates were incubated for 1 h at 37°C. After a final
washing with wash buffer (0.05% Tween 20 in PBS), 3,3=,5,5=-tetramethylbenzidine liquid substrate
solution (TMB; Millipore, Billerica, MA) was added (100 l per well) for 1 to 2 min, and the reaction was












aRestriction enzyme sites are underlined.
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then stopped by adding 1 N H2SO4 (Merck). The optical density was measured using an ELISA microplate
reader (Molecular Devices, San Jose, CA). The antibody titer was expressed as the reciprocal log2 titer of
dilution, showing an absorbance of 0.2 at 450 nm.
Pseudovirus production. HEK 293T/17 (ATCC, CRL-11268) cells were maintained in Dulbecco
modified Eagle medium (DMEM; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum
(FBS; Thermo Fisher Scientific) and 1% penicillin/streptomycin (Thermo Fisher Scientific) and incubated
at 37°C and 5% CO2. Cells at a concentration of 4  106 were seeded into 100-mm dishes at a ratio that
yielded 70 to 90% confluence at the time of transfection. Lentiviral pseudovirions expressing the
MERS-CoV S-protein were produced by cotransfection of 293T cells with three plasmids, 7 g of
transducing plasmid pHR=CMV-Luc, 7 g of packaging plasmid pCMV ΔR8.2 (35), and 100 ng of pCMV/R
8B-SΔER plasmid of the MERS-CoV EMC/2012 or KOR/KNIH/002 strain, using Lipofectamine 2000
transfection reagent (Thermo Fisher Scientific). The medium was replaced after overnight incubation.
Supernatants containing the pseudovirions were harvested 48 to 72 h after transfection, filtered through
a 0.45-m filter, and stored at 	80°C. Titration of the pseudovirus was performed using a lentivirus-
associated p24 ELISA kit (Cell Biolabs, San Diego, CA).
Pseudovirus neutralization. 786-O cells (ATCC, CRL-1932) were plated at a density of 1  104
cells/well in a 96-well plate with complete DMEM (10% FBS, 1% penicillin/streptomycin) at 37°C in a
humidified atmosphere of 5% CO2 the day before pseudoviral infection until 95% confluence was
reached. After incubation of 50 l of 2  106 pseudovirions with 20 l of serially diluted mouse immune
serum or neutralizing antibody as the positive control (Sino Biological) for 1 h at room temperature, the
mixtures were added to the cells. The wells were replenished with 100 l of fresh complete DMEM after
6 h of incubation. The cells were lysed after 72 h with 20 l of lysis buffer (Promega, Madison, WI) and
transferred to an opaque plate (Perkin-Elmer, Waltham, MA). Luciferase activity was measured by adding
40 l of the substrate (Promega) and using a SpectraMax L microplate reader (Molecular Devices).
IFN- ELISpot assay. Immunized C57BL/6 mice were sacrificed at 14 days after they received the last
immunization, and spleen lymphocytes were obtained from each mouse (36). Cells at concentrations of
1  106, 3.3  105, and 1.1  105 were transferred to each well of precoated BD ELISpot plates (BD
Bioscience). For stimulation, 5 g/ml of MERS S pooled peptides (seven different MERS-CoV S peptides
[S232, NH2-FNLRNCTFM-OH; S395, NH2-QVYNFKRL-OH; S434, NH2-ASNCYSSL-OH; S483, NH2-TVPHNLTTI-
OH; S773, NH2-LNSSYFKL-OH; S945, NH2-AAYTSSLL-OH; and S1165, NH2-IAPVNGYFI-OH]) were added,
followed by incubation for 16 h at 37°C in a 5% CO2 incubator. After discarding the cells and peptide
stimulants and washing, biotinylated anti-mouse IFN- (BD Bioscience) was added to each well, and the
plate was incubated at room temperature for 2 h. After the wells were washed, streptavidin-HRP (BD
Bioscience) was added, and the plate was incubated at room temperature for 1 h. After washing, AEC
substrate solution (BD AEC substrate reagent set; BD Biosciences) was added to each well. Spot
development was stopped by washing the wells with deionized water, and spots were counted by using
an ELISpot reader (Cellular Technology, Ltd., Cleveland, OH).
Wild-type MERS-CoV neutralization. VeroE6 cells were seeded at a density of 1  105 cells/well in
a 24-well plate with complete DMEM (10% FBS). The next day, the wild-type MERS-CoV KOR/KNIH/002
strain provided by Korea CDC was incubated with the serial dilutions of mouse sera at 37°C in a
humidified atmosphere of 5% CO2 for 1 h. Then, the virus-serum mixtures were added to the cells, and
1 ml of overlay mixture (1% methyl cellulose; Sigma) in DMEM containing 10% FBS) was added after 1
h of incubation at 37°C. After 3 days, the cells were fixed with 4% paraformaldehyde (Intron Biotech-
nology, Dedham, MA) and permeabilized with methanol (Merck). The cells were incubated with rabbit
anti-MERS-CoV N protein antibody (1:200; Sino Biological, Inc.) for 2 h at room temperature or overnight
at 4°C, washed, and incubated with goat anti-rabbit alkaline phosphatase (1:10,000, Thermo Fisher
Scientific) for 1 h at room temperature, followed by washing and incubation with the nitro-blue
tetrazolium and 5-bromo-4-chloro-3=-indolyphosphate (NBT-BCIP) substrate solution (Merck) for 20 min.
The plaques were counted, and the plaque reduction neutralization titer (PRNT50) was calculated.
Wild-type MERS-CoV challenge. hDPP4 knock-in mice were immunized two times with S (ΔER) DNA
plasmid (50 g) and boosted with alum adjuvanted S (ΔTM) recombinant protein (1 g) at 2-week
intervals. Control groups received the mock vector S (ΔER) DNA plasmid or S (ΔTM) protein three times.
Two weeks after the last immunization, the mice were challenged with the MERS-CoV KOR/KNIH/002
strain (20,000 PFU; 50 l) intranasally under anesthesia in the IVI BL3 lab. The survival and body weight
of each mouse was monitored daily.
Statistics. All statistical analyses were performed using Prism 8 (GraphPad, San Diego, CA). Differ-
ences between individual groups were evaluated using one-way analysis of variance. Differences
between the two groups were evaluated using a two-tailed Mann-Whitney U test. A log-rank (Mantel-
Cox) test was used to compare the survival rates after the challenge. Two-tailed P values of 0.05 were
considered statistically significant.
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